154 related articles for article (PubMed ID: 2575406)
21. Treatment with octreotide and bromocriptine in patients with acromegaly: an open pharmacodynamic interaction study.
Fredstorp L; Kutz K; Werner S
Clin Endocrinol (Oxf); 1994 Jul; 41(1):103-8. PubMed ID: 8050122
[TBL] [Abstract][Full Text] [Related]
22. Changes in plasma GH levels and clinical activity during bromocriptine therapy in acromegaly. The value of predictive tests.
Nortier JW; Croughs RJ; Donker GH; Thijssen JH; Schwarz F
Acta Endocrinol (Copenh); 1984 Jun; 106(2):175-83. PubMed ID: 6145276
[TBL] [Abstract][Full Text] [Related]
23. Abnormal growth hormone responsiveness to stimuli in women with active celiac sprue.
Peracchi M; Molteni N; Cantalamessa L; Bardella MT; Peracchi G; Orsatti A; Faggioli P; Bianchi PA
Am J Gastroenterol; 1992 May; 87(5):580-3. PubMed ID: 1595643
[TBL] [Abstract][Full Text] [Related]
24. A comparison of the effect of levodopa and somatostatin on the plasma levels of growth hormone, insulin, glucagon and prolactin in acromegaly.
Dunn PJ; Donald RA; Espiner EA
Clin Endocrinol (Oxf); 1976 Mar; 5(2):167-74. PubMed ID: 1269163
[TBL] [Abstract][Full Text] [Related]
25. Biological and clinical evaluation of lanreotide (BIM 23014), a somatostatin analogue, in the treatment of advanced breast cancer. A pilot study by the I.T.M.O. Group. Italian Trials in Medical Oncology.
Di Leo A; Ferrari L; Bajetta E; Bartoli C; Vicario G; Moglia D; Miceli R; Callegari M; Bono A
Breast Cancer Res Treat; 1995 Jun; 34(3):237-44. PubMed ID: 7579488
[TBL] [Abstract][Full Text] [Related]
26. Partial hypopituitarism and hyperprolactinemia: successful induction of ovulation with bromocriptine and human menopausal gonadotropins.
Dawood MY; Jarrett JC; Choe JK
Fertil Steril; 1982 Oct; 38(4):415-8. PubMed ID: 6811337
[TBL] [Abstract][Full Text] [Related]
27. SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years.
Lamberts SW; Uitterlinden P; del Pozo E
J Clin Endocrinol Metab; 1987 Oct; 65(4):703-10. PubMed ID: 2888785
[TBL] [Abstract][Full Text] [Related]
28. Bromocriptine treatment over 12 years in acromegaly: effect on growth hormone and prolactin secretion.
Rau H; Althoff PH; Schmidt K; Usadel KH
Acta Endocrinol (Copenh); 1992 Mar; 126(3):247-52. PubMed ID: 1574954
[TBL] [Abstract][Full Text] [Related]
29. The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients.
Lamberts SW; Oosterom R; Neufeld M; del Pozo E
J Clin Endocrinol Metab; 1985 Jun; 60(6):1161-5. PubMed ID: 2860119
[TBL] [Abstract][Full Text] [Related]
30. The combination therapy with bromocriptine and cyproheptadine in patients with acromegaly.
Hanew K; Sugawara A; Shimizu Y; Sato S; Sasaki A; Tazawa S; Ishii K; Saitoh T; Saso S; Yoshinaga K
Endocrinol Jpn; 1989 Jun; 36(3):429-38. PubMed ID: 2510991
[TBL] [Abstract][Full Text] [Related]
31. The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex.
van der Lely AJ; Harris AG; Lamberts SW
Clin Endocrinol (Oxf); 1992 Aug; 37(2):181-5. PubMed ID: 1395069
[TBL] [Abstract][Full Text] [Related]
32. Perioperative bromocriptine adjuvant treatment for operable breast cancer.
Fentiman IS; Brame K; Chaudary MA; Camplejohn RS; Wang DY; Millis RR
Lancet; 1988 Mar; 1(8586):609-10. PubMed ID: 2894547
[TBL] [Abstract][Full Text] [Related]
33. Cytocidal effects of bromocriptine, somatostatin analog, and heat on growth hormone-secreting pituitary adenoma in vitro.
Kawamoto K; Uozumi T; Sakoda K; Mukada K; Kurisu K; Yano T
Cancer; 1992 Jun; 69(11):2688-96. PubMed ID: 1571899
[TBL] [Abstract][Full Text] [Related]
34. The role of prolactin in the inhibitory action of bromocriptine on growth hormone secretion in acromegaly.
Lamberts SW; Klijn JG; van Vroonhoven CC; Stefanko SZ; Liuzzi A
Acta Endocrinol (Copenh); 1983 Aug; 103(4):446-50. PubMed ID: 6310918
[TBL] [Abstract][Full Text] [Related]
35. Acromegaly and hyperprolactinemia in a patient with polyostotic fibrous dysplasia: dynamic endocrine studies and treatment with the somatostatin analogue octreotide.
Garcia MB; Koppeschaar HP; Lips CJ; Thijssen JH; Krenning EP
J Endocrinol Invest; 1994 Jan; 17(1):59-65. PubMed ID: 7911814
[TBL] [Abstract][Full Text] [Related]
36. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status.
Cozzi R; Attanasio R; Lodrini S; Lasio G
Clin Endocrinol (Oxf); 2004 Aug; 61(2):209-15. PubMed ID: 15272916
[TBL] [Abstract][Full Text] [Related]
37. Growth enhancement by dopaminergic therapy in children with intrauterine growth retardation.
Huseman CA
J Clin Endocrinol Metab; 1985 Sep; 61(3):514-9. PubMed ID: 3926809
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of a long-acting injectable form of bromocriptine in patients with prolactin and growth hormone secreting macroadenomas.
Tsagarakis S; Tsiganou E; Tzavara I; Nikolou H; Thalassinos N
Clin Endocrinol (Oxf); 1995 Jun; 42(6):593-9. PubMed ID: 7634499
[TBL] [Abstract][Full Text] [Related]
39. Bromocriptine therapy in patients with acromegaly: effects on growth hormone, somatomedin A and prolactin.
Werner S; Hall K; Sjöberg HE
Acta Endocrinol Suppl (Copenh); 1978; 216():199-206. PubMed ID: 347862
[TBL] [Abstract][Full Text] [Related]
40. Treatment of acromegaly with bromocriptine.
Wang C; Chan V; Yeung RT
Aust N Z J Med; 1979 Jun; 9(3):225-32. PubMed ID: 288387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
